Regeneron Pharmaceuticals Inc. has emerged victorious in an antitrust lawsuit against Amgen Inc., with a federal court jury in Delaware finding that Amgen violated antitrust and tort laws. The jury concluded that Amgen engaged in a bundling scheme that unlawfully leveraged its anti-inflammatory drugs, Enbrel and Otezla, to persuade pharmacy benefit managers to exclusively select Repatha over Regeneron's Praluent in the PCSK9 category. This decision resulted in Amgen being found in violation of the Clayton Act, the Sherman Act, and several state laws. Consequently, Regeneron was awarded $135.6 million in compensatory damages and $271.2 million in punitive damages. Regeneron has expressed satisfaction with the verdict, emphasizing the importance of fair competition in ensuring patient access to innovative treatments.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。